Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis

Hong Pan, Ruikang Liu, Saroj Rai, Jiajia Liu, Yeming Zhou, Yu Zheng, Jin LiJournal of Orthopaedic Surgery and Research 2023 · DOI

This meta-analysis, published in the Journal of Orthopaedic Surgery and Research, evaluates whether the newer anabolic agent abaloparatide (ABL) outperforms the established standard, teriparatide (TPTD), in treating postmenopausal osteoporosis.

TL;DR

Abaloparatide (ABL) is more effective than teriparatide (TPTD) at increasing bone mineral density (BMD) in the hip and femoral neck after 24 weeks of treatment. Crucially, ABL also carries a 51% lower risk of inducing hypercalcemia (excess calcium in the blood) compared to TPTD, making it a potent and potentially safer alternative for high-risk patients.

What Problem Does This Paper Address?

Postmenopausal osteoporosis is a major public health challenge, leading to fragility fractures that significantly increase morbidity and mortality. While antiresorptive drugs (like bisphosphonates) are common, "anabolic" agents—which actively build new bone—are reserved for patients at very high fracture risk.

Teriparatide (TPTD) has long been the primary anabolic option. However, abaloparatide (ABL), a synthetic analog of parathyroid hormone-related protein (PTHrP), has emerged as a competitor. This paper addresses the clinical uncertainty regarding which drug is more effective at boosting bone mineral density (BMD) and which has a better safety profile, specifically regarding adverse events like hypercalcemia.

Methods

The authors conducted a systematic review and meta-analysis following PRISMA guidelines. They searched major databases (Medline, Embase, Cochrane, etc.) for Randomized Controlled Trials (RCTs) and post-hoc analyses comparing ABL to either a placebo or TPTD.

Key technical aspects included:

  • Quality Assessment: Used the Cochrane Risk of Bias (CROBAT) tool and the GRADE (Grading of Recommendations, Assessment, Development, and Evaluation) tool to weigh the strength of the evidence.
  • Statistical Analysis: Employed Weighted Mean Difference (WMD) for continuous outcomes (BMD change) and Odds Ratios (OR) for safety data.
  • Heterogeneity: Used $I^2$ statistics to determine whether to use fixed-effects or random-effects models.

Datasets

The study synthesized data from 4 RCTs and 12 post-hoc analyses, encompassing a total of 2,938 postmenopausal women. The primary source of high-quality data was the "ACTIVE" trial (Abaloparatide Comparator Trial In Vertebral Endpoints).

Key Insights and Ideas

  • Site-Specific Superiority: While both drugs are effective, ABL showed a statistically significant advantage over TPTD specifically at the total hip and femoral neck. This is clinically vital because hip fractures are often the most debilitating type of osteoporotic injury.
  • The Molecular "Why": The authors highlight that ABL (a PTHrP analog) has a different binding affinity for the PTH1 receptor than TPTD. It dissociates faster, which likely explains why it stimulates bone formation with less of the "resorptive" (bone-clearing) and hypercalcemic side effects seen with TPTD.
  • Safety Trade-offs: ABL significantly reduces the risk of hypercalcemia compared to TPTD. However, compared to a placebo, ABL is associated with higher rates of minor side effects like nausea and palpitations.

Key Results

  • BMD at 24 Weeks (ABL vs. TPTD):
    • Femoral Neck: WMD = 1.58 [0.52, 2.63] (High GRADE quality).
  • Total Hip: WMD = 1.46 [0.59, 2.32] (High GRADE quality).
  • Lumbar Spine: Results were comparable between the two drugs, though ABL was slightly less effective in some subgroups (likely due to dosage variations and high heterogeneity, $I^2=83\%$).
  • Safety: The incidence of hypercalcemia in the ABL group was 51% lower than in the TPTD group.
  • Fractures: While meta-analysis data was insufficient for a definitive conclusion on fracture rates, individual studies within the review (e.g., the ACTIVE trial) showed ABL reduced new vertebral and non-vertebral fractures more effectively than TPTD.

Limitations and Future Work

  • Industry Sponsorship: All four included RCTs were manufacturer-sponsored (Radius Health Inc.), which introduces a potential for bias. The authors call for independent, head-to-head trials from academic centers.
  • Small Sample of Trials: Although the total patient count is nearly 3,000, the data comes from only four primary trials.
  • Short-Term Focus: Most comparative data focused on the 24-week mark. Long-term (multi-year) efficacy and safety data for ABL versus TPTD are still needed.
  • Fracture Data: There was insufficient data to perform a robust meta-analysis specifically on fracture reduction; BMD was used as a proxy for efficacy.

Summary updated

Abstract

ABL demonstrated a beneficial effect on BMD compared to both placebo and TPTD for postmenopausal women with osteoporosis. ABL also had insignificantly lowered adverse event risk than TPTD. ABL is an alternative for patients with postmenopausal osteoporosis.
BibTeX
@article{pan2023is,
  author = {Hong Pan and Ruikang Liu and Saroj Rai and Jiajia Liu and Yeming Zhou and Yu Zheng and Jin Li},
  title = {{Is abaloparatide more efficacious on increasing bone mineral density than teriparatide for women with postmenopausal osteoporosis? An updated meta-analysis}},
  journal = {Journal of Orthopaedic Surgery and Research},
  year = {2023},
  doi = {10.1186/s13018-023-03595-x},
}
Figure